Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00596258 · ClinicalTrials.gov registry record · Phase 2
A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)
A Phase 2 study, sponsored by Tigris Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00596258 is a Phase 2 study that has completed, run by Tigris Pharmaceuticals. The registered enrollment target is 11 participants.
The verdict
NCT00596258, a Phase 2 study, has completed, sponsored by Tigris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth). The purpose of this study is to evaluate the safety and efficacy of A-007, when used to treat high-grade cervical dysplasia.
Interventions
- DRUG A-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-11 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00596258
The ClinicalTrials.gov registry entry for NCT00596258 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tigris Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which A-007 is the first listed.
NCT00596258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00596258 about?
NCT00596258 is a clinical study titled "A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)". A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth). The purpose of this study is to evaluate the safety and efficacy of A-007, when used to treat high-grade cervical dysplasia.
What is the current status of trial NCT00596258?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2007-11. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00596258?
The interventions under investigation include: A-007 (DRUG).
Who is sponsoring clinical trial NCT00596258?
This trial is sponsored by Tigris Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.